I'm still not quite sure if Cytodyn could not look
Post# of 154725
(Total Views: 1074)
Posted On: 05/03/2020 5:34:38 AM
I'm still not quite sure if Cytodyn could not look for a big partner after all - just because of the Herculean task!
I scanned the internet for Rantes and found this recently published interesting article from April 6, 2020 by investors / employees of GSK, among other things, Leronlimab is mentioned!
Extract from the NEJM translation (summary):
https://www.ncbi.nlm.nih.gov/pubmed/32343620
Original on Taylor & Francis online:
https://www.tandfonline.com/doi/full/10.1080/...20.1755069
Abstract:
Consistent with the challenging nature of delivering suitable quantities of GPCR in a clinically relevant conformation for the discovery of candidate-quality antibodies, only two anti-GPCR mAbs have been approved by the US Food and Drug Administration (FDA), specifically, mogamulizumab (POTELIGEO®), developed by Kyowa Hakko Kirin, an afucosylated (enhanced antibody-dependent cellular cytotoxicity) anti-CCR4 mAb for the treatment of cutaneous T-cell lymphoma,37 and erenumab (Aimovig®), co-developed by Amgen and Novartis, an anti-CGRP receptor mAb for the treatment of chronic migraine.38 Both mogamulizumab and erenumab were generated by immunization of mice with the relevant target N-termini; in the case of mogamulizumab, a linear synthetic peptide (aa 2–29) was used as antigen because of the short, relatively unstructured, N-terminus of CCR4,38 whereas erenumab was generated using a purified recombinant soluble form of the large N-terminus of CGRP, which co-purified with the accessory protein RAMP1 using a proprietary process.21 Other anti-GPCR mAbs are in late-stage clinical trials or pre-registration, including leronlimab (PRO-140), a humanized anti-CCR5 mAb undergoing regulatory review as a treatment for HIV infection, with additional clinical trials in progress or planned in acute GvHD (Phase 2) and metastatic triple-negative breast cancer (Phase 1b/2).2,5
GSK is the 7 largest pharmaceutical manufacturer worldwide, research in the field, Amgen and Novartis could also be considered!
GSK: https://de.wikipedia.org/wiki/GlaxoSmithKline
Amgen: The company's success is based on the use of recombinant DNA technology or biotechnology. This enables human proteins, e.g. B. to produce hormones or monoclonal antibodies using microorganisms. This technology is also used by other large biotechnology companies such as AbbVie, Biogen, Genentech, Genzyme, MSD, Roche and Sanofi.
https://en.wikipedia.org/wiki/Amgen
Cytodyn growing organically might will bring us more as shareholder, but we might need more patience, than partnering and growing fast!
Still at the end a buyout could occur!
IMO
I scanned the internet for Rantes and found this recently published interesting article from April 6, 2020 by investors / employees of GSK, among other things, Leronlimab is mentioned!
Extract from the NEJM translation (summary):
https://www.ncbi.nlm.nih.gov/pubmed/32343620
Original on Taylor & Francis online:
https://www.tandfonline.com/doi/full/10.1080/...20.1755069
Abstract:
Consistent with the challenging nature of delivering suitable quantities of GPCR in a clinically relevant conformation for the discovery of candidate-quality antibodies, only two anti-GPCR mAbs have been approved by the US Food and Drug Administration (FDA), specifically, mogamulizumab (POTELIGEO®), developed by Kyowa Hakko Kirin, an afucosylated (enhanced antibody-dependent cellular cytotoxicity) anti-CCR4 mAb for the treatment of cutaneous T-cell lymphoma,37 and erenumab (Aimovig®), co-developed by Amgen and Novartis, an anti-CGRP receptor mAb for the treatment of chronic migraine.38 Both mogamulizumab and erenumab were generated by immunization of mice with the relevant target N-termini; in the case of mogamulizumab, a linear synthetic peptide (aa 2–29) was used as antigen because of the short, relatively unstructured, N-terminus of CCR4,38 whereas erenumab was generated using a purified recombinant soluble form of the large N-terminus of CGRP, which co-purified with the accessory protein RAMP1 using a proprietary process.21 Other anti-GPCR mAbs are in late-stage clinical trials or pre-registration, including leronlimab (PRO-140), a humanized anti-CCR5 mAb undergoing regulatory review as a treatment for HIV infection, with additional clinical trials in progress or planned in acute GvHD (Phase 2) and metastatic triple-negative breast cancer (Phase 1b/2).2,5
GSK is the 7 largest pharmaceutical manufacturer worldwide, research in the field, Amgen and Novartis could also be considered!
GSK: https://de.wikipedia.org/wiki/GlaxoSmithKline
Amgen: The company's success is based on the use of recombinant DNA technology or biotechnology. This enables human proteins, e.g. B. to produce hormones or monoclonal antibodies using microorganisms. This technology is also used by other large biotechnology companies such as AbbVie, Biogen, Genentech, Genzyme, MSD, Roche and Sanofi.
https://en.wikipedia.org/wiki/Amgen
Cytodyn growing organically might will bring us more as shareholder, but we might need more patience, than partnering and growing fast!
Still at the end a buyout could occur!
IMO
(1)
(0)